PRINS: A Drug Target / Disease Biomarker (G100169750)

Target Name: PRINS

NCBI ID: G100169750

PRINS

Other Name(s): NCRNA00074 | psoriasis associated non-protein coding RNA induced by stress | Psoriasis susceptibility-related noncoding RNA

PRINS: A Drug Target / Disease Biomarker

PRINS is a drug target and a biomarker that is being studied for its potential utility in treating various neurological disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. PRINS is a protein that is expressed in the brain and has been shown to play a role in the development and progression of these disorders.

Recent studies have shown that PRINS can be used to treat certain neurological disorders by inhibiting its activity. This is done through a process called small molecule inhibition, which involves using small molecules to stop the activity of PRINS. One of the small molecules that has been shown to be effective in inhibiting PRINS activity is called TAPI2.

TAPI2 is a protein that is expressed in the brain and has been shown to interact with PRINS. When TAPI2 is introduced into the brain, it can inhibit the activity of PRINS, which can potentially lead to the reversal of neurodegeneration in the brain. This is because TAPI2 can help to protect the brain cells from the damaging effects of PRINS.

Another small molecule that has been shown to be effective in inhibiting PRINS activity is called S100尾. S100尾 is a protein that is expressed in the brain and has been shown to interact with PRINS. When S100尾 is introduced into the brain, it can also inhibit the activity of PRINS, which can potentially lead to the reversal of neurodegeneration in the brain.

In addition to its potential use as a drug target and biomarker, PRINS has also been shown to have potential in treating other neurological disorders. For example, PRINS has been shown to be involved in the development and progression of Alzheimer's disease, and studies have shown that inhibiting its activity can potentially reverse the neurodegeneration associated with this disease.

PRINS has also been shown to be involved in the development and progression of Parkinson's disease, and studies have shown that inhibiting its activity can potentially reverse the neurodegeneration associated with this disease.

Overall, PRINS is a protein that has the potential to be a drug target and biomarker for treating a variety of neurological disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. Further research is needed to fully understand its potential utility and to develop safe and effective treatments.

Protein Name: Psoriasis Associated Non-protein Coding RNA Induced By Stress

The "PRINS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRINS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets